Profitability Ratios
| Ratio |
Value |
| GP Margin |
55.7% |
| EBIT Margin |
11.7% |
| EBITDA Margin |
20.1% |
| Operating Margin |
18.1% |
| Pretax Margin |
9.6% |
| Cont. Ops Margin |
7.3% |
| Net Margin |
7.3% |
| Bottom Line Margin |
7.3% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.95 |
| Quick Ratio |
1.87 |
| Solvency Ratio |
0.131 |
| Cash Ratio |
0.87 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.69 |
| Forward PEG |
-0.69 |
| Price/Book |
3.20 |
| Price/Sales |
1.91 |
| Price/FCF |
9.79 |
| Price/Op Cash Flow |
8.69 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.5111 |
| Debt/Equity |
1.5378 |
| Debt/Capital |
0.6060 |
| Long-Term Debt/Capital |
0.6050 |
| Financial Leverage |
3.01 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
2.93 |
| Operating Cash Flow Ratio |
1.038 |
| Operating Cash Flow/Sales |
22.0% |
| Free Cash Flow/Operating Cash Flow |
88.8% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
7.05 |
| Interest Coverage |
8.4100 |
| Short-Term Operating Cash Flow Coverage |
58.47 |
| Operating Cash Flow Coverage |
0.24 |
| Capital Expenditure Coverage |
8.95 |
| Dividend + Capital Expenditure Coverage |
8.95 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
28.28 |
| EPS |
2.063 |
| Debt/Share |
26.5644 |
| Cash/Share |
5.20 |
| Book Value/Share |
16.88 |
| Tangible BV/Share |
-6.52 |
| Equity/Share |
16.88 |
| Operating Cash Flow/Share |
6.215 |
| Capital Expenditure/Share |
0.695 |
| FCF/Share |
5.520 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.760 |
| Earnings Before Tax/EBIT |
0.530 |
| Price/Fair Value |
3.20 |
| Debt/Market Cap |
0.4803 |
| Effective Tax Rate |
24.0% |
| Enterprise Value Multiple |
13.14 |
HAE - Haemonetics Corporation